Home | Business News | Browse by Publication | P | Pharma Marketletter

Positive data from Ph III study of Roche's Bonviva/Boniva.

Publication: Pharma Marketletter
Publication Date: 12-JUL-04
Format: Online
Delivery: Immediate Online Access
Full Article Title: Positive data from Ph III study of Roche's Bonviva/Boniva.(evaluating an intravenous injection of Bonviva/Boniva)

Article Excerpt
Swiss drug major Roche has reported positive results from the first year of a Phase III study, known as DIVA (Dosing IntraVenous Administration), evaluating an intravenous injection of Bonviva/Boniva (ibandronate) with extended intervals between dosages, for the treatment of post-menopausal osteoporosis.

The DIVA trial is a two-year international study...



More articles from Pharma Marketletter
Jerini's icatibant gets Orphan Drug Status from FDA.(Food and Drug Adm..., July 12, 2004
Cytorex completes Cytoreg cytotoxicity tests.(Cytorex Biosciences)(Bri..., July 12, 2004
Pharmion launches Vidaza in the USA.(Brief Article), July 12, 2004

Looking for additional articles?
Search our database of over 3 million articles.

Looking for more in-depth information on this industry?
Search our complete database of Industry & Market reports by text, subject, publication name or publication date.

About Goliath
Whether you're looking for sales prospects, competitive information, company analysis or best practices in managing your organization, Goliath can help you meet your business needs.

Our extensive business information databases empower business professionals with both the breadth and depth of credible, authoritative information they need to support their business goals. Whether it be strategic planning, sales prospecting, company research or defining management best practices - Goliath is your leading source for accurate information.